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Abstract
Background: The Tet-Off (tTA) and Tet-On (rtTA) regulatory systems are widely applied to
control gene expression in eukaryotes. Both systems are based on the Tet repressor (TetR) from
transposon Tn10, a dimeric DNA-binding protein that binds to specific operator sequences (tetO).
To allow the independent regulation of multiple genes, novel Tet systems are being developed that
respond to different effectors and bind to different tetO sites. To prevent heterodimerization when
multiple Tet systems are expressed in the same cell, single-chain variants of the transactivators have
been constructed. Unfortunately, the activity of the single-chain rtTA (sc-rtTA) is reduced when
compared with the regular rtTA, which might limit its application.
Results:  We recently identified amino acid substitutions in rtTA that greatly improved the
transcriptional activity and doxycycline-sensitivity of the protein. To test whether we can similarly
improve other TetR-based gene regulation systems, we introduced these mutations into tTA and
sc-rtTA. Whereas none of the tested mutations improved tTA activity, they did significantly
enhance sc-rtTA activity. We thus generated a novel sc-rtTA variant that is almost as active and
dox-sensitive as the regular dimeric rtTA. This variant was also less sensitive to interference by co-
expressed TetR-based tTS repressor protein and may therefore be more suitable for applications
where multiple TetR-based regulatory systems are used.
Conclusion:  We developed an improved sc-rtTA variant that may replace regular rtTA in
applications where multiple TetR-based regulatory systems are used.
Background
Inducible gene regulation systems that utilize small, non-
toxic effector molecules to control transgene expression in
eukaryotic cells and organisms have become invaluable
tools in many biological research areas, such as functional
genomics and gene therapy. Among the currently used
regulatory circuits, the Tet-Off and Tet-On systems based
on the tetracycline-resistance determinant from transpo-
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son Tn10 are the most widely applied and best studied [1-
3]. In Escherichia coli, the Tet repressor protein (TetR)
forms a dimer that binds to the tet operator (tetO) DNA
sequence with high affinity and specificity. Tetracycline
(Tc) or its derivative doxycycline (dox) binds to TetR and
triggers a conformational change that prevents the protein
from binding to tetO. Fusion of TetR to the VP16 activa-
tion domain of herpes simplex virus resulted in the Tc-
responsive transactivator (tTA) which has retained the
DNA-binding specificity and effector-inducibility of TetR
[4]. In the absence of effector, tTA binds to tetO and acti-
vates transcription from an appropriately-positioned min-
imal promoter. Administration of Tc or dox switches gene
expression off (Tet-Off system). tTA variants have been
isolated that carry amino acid substitutions in the TetR
part and exhibit a reverse phenotype [5,6] (Fig. 1). These
reverse tTAs (rtTAs) activate gene expression from tetO-
containing minimal promoters only in the presence of
dox (Tet-On system). Both Tet systems have been used to
regulate gene expression in a wide variety of applications
[2]. TetR has also been fused to the KRAB repression
domain of the human Kox1 protein to form a Tc-respon-
sive transsilencer (tTS), which can actively suppress back-
ground gene expression from tetO-containing minimal
promoters in the absence of dox [7]. The combined use of
tTS and rtTA has resulted in more stringent dox-control of
target genes [8,9]. In such systems, the Tn10-derived TetR
moiety of tTS was replaced with other natural TetR vari-
ants to prevent heterodimerization with rtTA [8-11].
Current research focuses on developing additional TetR-
based transregulators that respond to specific Tc-deriva-
tives and recognize distinct operator sequences [12-16].
Such novel Tet systems will allow the independent regula-
tion of multiple (sets of) genes by different effectors
[16,17]. Again, the formation of heterodimers has to be
prevented. Transfer of the mutations responsible for the
altered phenotypes to other natural sequence variants rep-
resents one strategy, but such changes can lead to non-
functional transregulators [17,18]. As an alternative strat-
egy, single-chain Tet transregulators have recently been
developed in which two TetR domains are connected by a
flexible peptide linker, and a single functional domain,
like an activation, repression or oligomerization domain
is fused to the C-terminus [18-20] (Fig. 1). These transreg-
ulators fold intramolecularly and do not dimerize with
each other. Unfortunately, the single-chain version of rtTA
(sc-rtTA) exhibits reduced activity when compared with
the dimeric rtTA, and this may restrict its application [18].
We have previously incorporated the rtTA2S-S2 gene
encoding a second-generation rtTA variant [6] and the
tetO elements into the HIV-1 genome to control virus rep-
lication [21,22]. During culturing of this dox-dependent
virus, spontaneous evolution selected for improved virus
variants in which the introduced Tet-On system was
found to be optimized [23-27]. We have identified several
amino acid substitutions that greatly enhance the tran-
scriptional activity and dox-sensitivity of rtTA [24,26]. To
test whether these mutations can similarly improve other
TetR-based transactivators, they were introduced into tTA
and sc-rtTA. Whereas none of these mutations improve
tTA activity, they all enhance sc-rtTA activity. The most
active sc-rtTA variant that we generated is 30-fold more
active than the original sc-rtTA, and almost as active as the
regular rtTA.
TetR-based transactivators Figure 1
TetR-based transactivators. (A) tTA contains the N-ter-
minal transposon Tn10-derived Tet repressor and the C-ter-
minal herpes simplex virus VP16-derived activation domain 
(AD). The TetR part can be subdivided in a DNA-binding 
domain (BD) and a regulatory core domain (core). rtTA 
(rtTA2S-S2 in ref. [6]) is a tTA variant with four amino acid 
substitutions in the TetR domain (shown above the protein). 
The mutations that enhance rtTA activity are also located in 
the TetR domain (shown under the protein). sc-rtTA is a sin-
gle-chain version of rtTA that contains two TetR moieties 
connected head to tail by a peptide linker and a single activa-
tion domain at the C-terminal end. (B) Both tTA and rtTA 
are active as homodimers, whereas sc-rtTA folds intramo-
lecularly.
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Results
Mutations that enhance rtTA activity do not improve tTA 
activity
The transactivators tTA and rtTA are fusion proteins con-
taining an N-terminal domain consisting of the TetR pro-
tein from transposon Tn10  and a C-terminal herpes
simplex virus VP16-derived activation domain. The acti-
vation domains are identical in both proteins, whereas the
TetR domains differ from each other by four amino acids
(Fig. 1A). We have used viral evolution to optimize the
function of the Tet-On system, and identified several
amino acid substitutions in the rtTA protein (rtTA2S-S2
[6]) that greatly enhance its transcriptional activity and
dox-sensitivity [24,26] (Fig. 1A). To test whether these
amino acid substitutions could similarly improve tTA, we
introduced the V9I, F67S, F86Y and G138D mutations
and compared the activity of these variants with that of
the wild-type tTA (tTA2S [6]). The tTA expression plasmids
were transfected into HeLa X1/6 cells containing chromo-
somally integrated copies of the CMV-7tetO  luciferase-
reporter construct [28]. Transfected cells were cultured at
different dox concentrations for two days. We subse-
quently determined the intracellular luciferase level,
which reflects tTA activity (Fig. 2). Wild-type tTA shows
high transcriptional activity without dox, and its activity is
gradually reduced with increasing dox concentrations. For
example, the activity is reduced to 30% at 0.1 ng/ml dox,
and 0.2% residual activity is observed at 2 ng/ml dox. All
variants show a transcriptional activity similar to wild-
type tTA in the absence of dox, but they respond differen-
tially to the presence of dox. While the V9I and F67S vari-
ants are similarly inhibited by dox as wild-type tTA, the
F86Y and G138D variants are less efficiently inhibited.
The F86Y and G138D variants show more than 80% resid-
ual activity at 0.1 ng/ml dox, and 50% and 7% residual
activity, respectively, at 2 ng/ml dox. These results demon-
strate that mutations beneficial for rtTA do not necessarily
improve tTA activity. In fact, the F86Y and G138D muta-
tions reduce the dox-sensitivity of tTA.
Mutations observed in rtTA can improve sc-rtTA activity
In sc-rtTA, two TetR moieties are connected head to tail by
a peptide linker, and a single activation domain is fused to
the C-terminus (Fig. 1). The mutations that did improve
rtTA activity are all positioned within the TetR part of the
transactivator. To test whether these beneficial mutations
can also improve the activity and dox-sensitivity of sc-
rtTA, we introduced them into a single (N- or C-terminal)
or both TetR moieties. The activity of these three sets of
variants was analyzed in HeLa X1/6 cells and compared
with the activity of the wild-type sc-rtTA (sc-rtTA2-S2) and
the regular rtTA (rtTA2S-S2) (Fig. 3). Both the wild-type sc-
rtTA and the regular rtTA show no background activity
without dox, and their activity gradually increases with
increasing dox levels. However, the induced activity of sc-
rtTA is lower than that of rtTA at all dox concentrations
tested. For example, sc-rtTA is about 40-fold less active
than rtTA at 1000 ng/ml dox. Introduction of the F86Y
mutation in the N-terminal TetR domain increased sc-
rtTA activity ~10-fold at all dox levels, but did not affect
background activity (Fig. 3A). The additional introduc-
tion of the V9I mutation into the F86Y variant only mar-
ginally improved sc-rtTA activity, whereas the addition of
the F67S, G138D, or V9I plus G138D mutations further
improved sc-rtTA activity ~2-fold at all dox levels. The
background activity of these variants was not increased.
Similar results were obtained upon introduction of the
mutations in the C-terminal TetR part (Fig. 3B). However,
none of these variants are as active as their counterparts
with mutations in the N-terminal TetR moiety. The F86Y
mutation increased sc-rtTA activity ~3-fold, and the addi-
tion of the F67S, G138D, or V9I plus G138D mutations
further increased activity ~2-fold. These results demon-
strate that the activity of sc-rtTA can be improved by muta-
tions in either TetR moiety, but mutations in the N-
terminal TetR domain have a larger impact on activity
than the same mutations in the C-terminal domain.
Introduction of the mutations in both TetR parts resulted
in the most active sc-rtTA variants (Fig. 3C). All these var-
iants demonstrate a higher transcriptional activity than
the corresponding variants with mutations in only one of
the two TetR moieties. For instance, the sc-rtTA with the
F86Y mutation in both TetR moieties is ~13-fold more
active than wild-type sc-rtTA at 1000 ng/ml dox, whereas
the same mutation in the N-terminal or in the C-terminal
TetR domain increased sc-rtTA activity ~10-fold and ~3-
fold, respectively. The variants containing the F67S,
G138D, or V9I plus G138D mutations in addition to the
F86Y mutation in both TetR moieties demonstrate an up
to 30-fold increased activity at 1000 ng/ml dox. Moreover,
these variants are particularly more sensitive to low dox
levels. To compare the dox-sensitivity of the sc-rtTA vari-
ants, we calculated the dox concentration that each vari-
ant needs to reach an activity similar to that of the wild-
type sc-rtTA at 1000 ng/ml dox (set at 100% in Fig. 4). The
lower the required dox concentration, the more sensitive
the variant is toward dox. For example, the variant carry-
ing the F67S and F86Y mutations in both TetR moieties
requires only 16 ng/ml dox to reach this 100% activity
level, which reflects a 62-fold higher dox-sensitivity than
the wild-type sc-rtTA. This variant thereby becomes the
most dox-sensitive and most active sc-rtTA (30-fold more
active than the wild-type, Fig. 4). In fact, both the tran-
scriptional activity and dox-sensitivity of this sc-rtTA vari-
ant are similar to that of the original dimeric rtTA.BMC Biotechnology 2007, 7:6 http://www.biomedcentral.com/1472-6750/7/6
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New sc-rtTA variants improve dox-control in combined 
activation/repression system
In the HeLa X1/6 cell line, the CMV-7tetO  luciferase-
reporter construct is stably integrated into the chromo-
some and shows no background activity in the absence of
dox. However, when this reporter construct is transiently
transfected into cells, multiple copies will be present,
which may increase background activity and thus reduce
inducibility (i.e. reduce the ratio between dox-induced
and uninduced promoter activity). We therefore tested the
new sc-rtTA variants with mutations in both TetR domains
upon transient cotransfection of C33A cells with the
CMV-7tetO  luciferase-reporter construct (Fig. 5). As
observed with HeLa X1/6 cells, the dox-induced activity of
the new sc-rtTA variants in C33A cells is higher than that
of the wild-type sc-rtTA, and the new variants are almost
as active as the regular rtTA, while the background activity
is not affected by the introduced mutations. However, this
background promoter activity is relatively high (~7%) and
as a consequence the inducibility is low with all rtTA and
sc-rtTA variants (16–69 fold).
Since the background expression from tetO-controlled
minimal promoters can be actively suppressed by tTS
[8,9], we cotransfected C33A cells with a tTS expression
plasmid (tTSS [18]). The presence of tTS indeed reduced
the background activity more than 20-fold (~0.3% resid-
ual activity in the absence of dox; Fig. 5). Administration
of dox inactivates tTS and activates the (sc-)rtTAs. The dox-
induced activity of rtTA and the wild-type sc-rtTA was
Mutations that enhance rtTA activity do not improve tTA activity Figure 2
Mutations that enhance rtTA activity do not improve tTA activity. The transcriptional activity of tTA variants was 
measured in HeLa X1/6 cells [28] containing chromosomally integrated copies of the CMV-7tetO luciferase reporter construct. 
Cells were transfected with the tTA expression plasmids indicated or pBluescript (-) as a negative control and a plasmid consti-
tutively expressing Renilla luciferase to correct for differences in transfection efficiency. Cells were cultured in the presence of 
different dox concentrations (0–20 ng/ml). The ratio of the firefly and Renilla luciferase activities measured two days after trans-
fection reflects the tTA activity. All values were related to the original (wild-type) tTA activity in the absence of dox, which was 
arbitrarily set at 100%. Average values of two transfections are shown with the error bars indicating the standard deviations.
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Mutations observed in rtTA can improve sc-rtTA activity Figure 3
Mutations observed in rtTA can improve sc-rtTA activity. The transcriptional activity of rtTA and sc-rtTA was meas-
ured in HeLa X1/6 cells, see Fig. 2 for details. Cells were cultured in the presence of different dox concentrations (0–1000 ng/
ml). All values were related to the original (wild-type) sc-rtTA activity at 1000 ng/ml dox, which was arbitrarily set at 100%. 
Average values of two transfections are plotted with the error bars indicating the standard deviations.
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however ~5-fold reduced by the presence of tTS. This may
be due to heterodimerization between the tTS and rtTA or
sc-rtTA molecules [29]. The dox-induced activity of the
new sc-rtTA variants was not affected by the presence of
tTS. The low background and high dox-induced activity
observed when combining the new sc-rtTA variants with
tTS results in a high inducibility (809–1193 fold),
whereas combining the wild-type sc-rtTA or regular rtTA
with tTS yields a much lower inducibility (99 and 273
fold, respectively). The highest inducibilty is obtained
with the F67S/F86Y-mutated sc-rtTA variant, which was
also the most active and dox-sensitive variant when tested
without tTS.
Discussion
We recently identified amino acid substitutions in rtTA
that greatly improve the transcriptional activity and dox-
sensitivity of the transactivator [24]. In this study, we
tested whether these mutations similarly affect other TetR-
based transactivators. The results demonstrate that
whereas none of the mutations that we tested improved
tTA activity, all mutations did enhance sc-rtTA activity sig-
nificantly. The F67S/F86Y-mutated sc-rtTA proved to be
the most active and dox-sensitive single-chain variant and
was as active and dox-sensitive as the original dimeric
rtTA.
Combining the rtTA and sc-rtTA variants with the repres-
sor tTS reduced the background activity of the CMV-7tetO
promoter. The dox-induced activity of the regular rtTA
and the wild-type sc-rtTA was also reduced in the presence
of tTS. This may be due to heterodimerization between
the tTS and rtTA or sc-rtTA molecules, which are all based
on the TetR class B from transposon Tn10. For sc-TetR and
Transcriptional activity and dox-sensitivity of the sc-rtTA variants Figure 4
Transcriptional activity and dox-sensitivity of the sc-rtTA variants. Calculation is based on the data of Fig. 3. Tran-
scriptional activity observed at 1000 ng/ml dox is shown as average value of two transfections with error bars indicating the 
standard deviations (wild-type sc-rtTA activity set at 100%). Dox-sensitivity is compared with the wild-type sc-rtTA (set at 1). 
For each variant, the dox concentration (ng/ml) that results in an activity comparable to that of the wild-type sc-rtTA activity at 
1000 ng/ml dox is indicated between brackets.
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for sc-tTS, heterodimer formation is not observed [18],
but this was not tested for sc-rtTA variants. The dox-
induced activity of the new sc-rtTA variants was not
affected by the presence of tTS. The introduced mutations
may have modified the sc-rtTA dimerization surface indi-
rectly, as none of the altered amino acids contribute
directly to dimerization, or they may have improved
intramolecular folding, thus preventing binding to tTS.
This resistance to interference by other TetR-based tran-
sregulators makes the new sc-rtTA variants very useful in
applications where multiple TetR-based regulatory sys-
tems are used simultaneously.
The fact that the mutations do not similarly affect tTA and
rtTA is probably due to structural differences between the
two proteins. In tTA, the natural TetR conformation and
dox-response are preserved. In rtTA, the TetR part contains
four amino acid substitutions that cause a reciprocal dox-
response. These amino acid substitutions do not only con-
fer the reverse phenotype, but also result in a 100-fold
reduced dox-sensitivity [3]. This suggests that the structure
of the mutated TetR is not optimal for the function of
rtTA. The mutations identified in the viral evolution
experiments may compensate for such unwanted tTA to
rtTA structural changes, and thus specifically enhance rtTA
activity. While the V9I mutation in the DNA-binding
domain is likely to increase the dox-induced binding
affinity of rtTA for the tetO  site, the F67S, F86Y, and
G138D mutations positioned in the regulatory core
domain may increase the binding affinity for dox or facil-
itate the structural transition to the DNA-binding form
[24,26]. In contrast, the structure of TetR in tTA is the
product of natural evolution of bacterial Tc-resistance reg-
ulation. Apparently, introduction of the selected muta-
tions into this already-optimized sequence has no (V9I
and F67S) or a detrimental effect (F86Y and G138D). The
reduced dox-responsiveness of the F86Y and G138D
mutated tTAs is in agreement with previous TetR-muta-
tion studies demonstrating that amino acid substitutions
at positions 86 and 138 can cause an induction-deficient
phenotype [30].
Both the transactivators rtTA and sc-rtTA are activated by
dox. However, the induced activity of sc-rtTA is reduced
when compared with rtTA [18]. This is probably due to
structural differences between these two proteins. First, sc-
rtTA contains only one activation domain per active mol-
ecule, whereas the rtTA dimer contains two activation
Combinatorial regulation of gene expression by sc-rtTA and tTS Figure 5
Combinatorial regulation of gene expression by sc-rtTA and tTS. Transcription from the CMV-7tetO luciferase 
reporter construct was measured upon transfection of C33A cells with the indicated rtTA, sc-rtTA (wild-type or with muta-
tions in both TetR domains) and tTS expression plasmids or pBluescript (-) as a negative control, and a plasmid constitutively 
expressing Renilla luciferase to correct for differences in transfection efficiency. Cells were cultured with (1000 ng/ml) or with-
out dox. The ratio of the firefly and Renilla luciferase activities measured two days after transfection reflects the rtTA activity. 
All values were related to the original (wild-type) sc-rtTA activity at 1000 ng/ml dox, which was arbitrarily set at 100%. Aver-
age values of three transfections are plotted with the error bars indicating the standard deviations. The ratio between the 
induced (+ dox) and uninduced (no dox) promoter activity (fold induction) is indicated on top of the bars.
0.1
1
10
100
1000
123456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6
 -
 +
T
r
a
n
s
c
r
i
p
t
i
o
n
a
l
 
a
c
t
i
v
i
t
y
 
(
%
)
rtTA - wild-type V9I F86Y F67S
F86Y
F86Y V9I F86Y
G138D
F86Y
G138D
-+ tTS: -+-+-+-+-+-+-+
sc rtTA:
dox
-
+
1
21
16
99
43 819 29 809 45 1193 35 886 38 978 69
273BMC Biotechnology 2007, 7:6 http://www.biomedcentral.com/1472-6750/7/6
Page 8 of 9
(page number not for citation purposes)
domains. Second, the two TetR parts of sc-rtTA are con-
nected by a peptide linker. Although the linker was
designed to be flexible, it may still interfere with the func-
tion of the TetR moieties. Our results demonstrate that the
sc-rtTA activity can be significantly improved by introduc-
tion of mutations that enhanced rtTA activity, suggesting
that sc-rtTA folds very similarly to rtTA.
The most active sc-rtTA variant in this study was obtained
by introducing beneficial mutations in both TetR
domains. The single-chain characteristic of sc-rtTA allows
the modification of a single TetR part. We demonstrated
that sc-rtTA can be improved by mutations in only one of
the TetR moieties, and that the introduction of the muta-
tions in the second TetR domain has an additive effect.
This suggests that dox binding to one of the effector-bind-
ing pockets does not affect binding to the second one,
which is in agreement with published data showing that
the binding of two Tc molecules to a TetR dimer occurs
without significant cooperativity [31]. The sc-rtTA variants
with beneficial mutations in the N-terminal TetR domain
appeared to be more active than the variants with the
same mutations in the C-terminal TetR part. This may
indicate that the induction of the C-terminal TetR domain
contributes less to the induced activity of sc-rtTA. Possi-
bly, it binds less efficiently to the tetO site due to the close
proximity of the DNA-binding domain to the linker pep-
tide.
Conclusion
We generated a novel sc-rtTA variant that is more active
and more dox-sensitive than the original sc-rtTA, and does
not show any background activity in the absence of dox.
This novel sc-rtTA is almost as active and dox-sensitive as
the regular dimeric rtTA but is less sensitive to interference
by other TetR-based transregulators, and may therefore be
more suitable for applications where multiple TetR-based
regulatory systems are used.
Methods
Construction of tTA variants
The plasmid pCMV-tTA contains the tTA2S gene cloned in
the expression vector pUHD141-1/X [6]. Mutations were
introduced in pCMV-tTA by mutagenesis PCR [32] with
the mutagenic primers (primer M) tTA-V9I (5'-GGACAA-
GAGCAAAATCATAAACTCTGCTCTGGA-3', mismatching
nucleotide underlined), tTA-F67S (5'-CATACCCACTCCT-
GCCCCCTGGAAGGCGA-3'), tTA-F86Y (5'-GCG-
GAACAACGCCAAGTCATACCGCTGTGCT-3'), or tTA-
G138D (5'-GTCCGCCGTGGACCACTTTACACTGGGCT-
3') and the primers 5'-TGGAGACGCCATCCACGCT-3'
(primer 1), 5'-TGAAATCGAGTTTCTCCAGGCCACAT-
ATGA-3' (primer 2), and 5'-TCACTGCATTCTAGTTGT-
GGT-3' (primer 3). Briefly, PCR reactions were performed
with primer M plus primer 3, and with primer 1 plus
primer 2. The PCR products were purified, mixed, and
PCR amplified with primers 1 and 3 (see ref. [32] for
details). The resulting mutated tTA genes were cloned as
EcoRI-BamHI fragments into pCMV-tTA. All constructs
were verified by sequence analysis.
Construction of sc-rtTA variants
The plasmids pCMV-rtTA and pCMV-sc-rtTA contain the
rtTA2S-S2 and sc-rtTA2-S2 genes, respectively, cloned in
the expression vector pUHD141-1/X [6,18]. The sc-rtTA
gene contains two TetR moieties and a single activation
domain. To introduce mutations into the N-terminal tetR
gene (with synthetic humanized codon usage), the EcoRI-
BfuAI fragment of pCMV-sc-rtTA was replaced with the
corresponding fragment of the appropriate pCMV-rtTA
plasmid [26]. Mutations were introduced into the C-ter-
minal tetR gene (with original bacterial codon usage) by
mutagenesis PCR [32] on pCMV-sc-rtTA with the muta-
genic primers (primer M) sc-rtTA-V9I (5'-
GGCTCTAGATCTCGTTTAGATAAAAGTAAAATCAT-
TAACAGCGCA-3'), sc-rtTA-F67S (5'-AGGCACCATACT-
CACTCTTGCCCTTTA-3'), sc-rtTA-F86Y (5'-
AACGCTAAAAGTTATAGATGTGCT-3'), or sc-rtTA-G138D
(5'-CAGCGCTGTGGACCACTTTACTTTA-3') and the
primers 5'-TAATCATATGTGGCCTGGAGAA-3' (primer
1), 5'-AGGCGTATTGATCAATTCAAGGCCGAATAAG-3'
(primer 2), and 5'-TCACTGCATTCTAGTTGTGGT-3'
(primer 3). The final PCR products were digested with
BglII and SmaI and used to replace the corresponding
fragment of pCMV-sc-rtTA. All constructs were verified by
sequence analysis.
Cell culture and (r)tTA activity assay
The activity of tTA, tTS, rtTA and sc-rtTA was assayed in
C33A cells (ATCC HTB31) [33] and HeLa X1/6 cells [28],
which are HeLa-derived cells containing chromosomally
integrated copies of the CMV-7tetO  luciferase reporter
construct pUHC13-3 [4]. Cells were cultured at 37°C with
5% CO2 in Dulbecco's modified Eagle's medium supple-
mented with 10% fetal calf serum, minimal essential
medium nonessential amino acids, penicillin (100 U/ml),
and streptomycin (100 µg/ml). Cells were grown in 2-cm2
wells to 60% confluency and transfected with the pCMV-
tTA, pCMV-tTS (pWHE122sB, [18]), pCMV-rtTA or
pCMV-sc-rtTA expression plasmids and the plasmid pRL-
CMV (Promega) by the calcium phosphate precipitation
method. pRL-CMV expresses Renilla luciferase from the
CMV promoter and was used as an internal control to
allow correction for differences in transfection efficiency.
1 µg of the DNA mixture in 15 µl water was mixed with 25
µl of 50 mM HEPES (pH 7.1)-250 mM NaCl-1.5 mM
Na2HPO4 and 10 µl of 0.6 M CaCl2, incubated at room
temperature for 20 min, and added to the culture
medium. The DNA mixture contained 8 ng pCMV-tTA
and 2.5 ng pRL-CMV for the tTA activity assay, 20 ngBMC Biotechnology 2007, 7:6 http://www.biomedcentral.com/1472-6750/7/6
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pCMV-sc-rtTA or pCMV-rtTA and 2 ng pRL-CMV for the
sc-rtTA or rtTA activity assay in HeLa X1/6 cells, and 5 ng
pCMV-sc-rtTA or pCMV-rtTA, 20 ng pCMV-7tetO-luci-
ferase (pUHC13-3) [4], 0.5 ng pRL-CMV and 200 ng
pCMV-tTS (when indicated) for the sc-rtTA or rtTA activity
assay in C33A cells. The DNA mixture was completed to 1
µg with pBluescript as carrier DNA. Cells were cultured
after transfection for 48 hours at different dox (D-9891,
Sigma) concentrations and then lysed in Passive Lysis
Buffer (Promega). Firefly and Renilla luciferase activities
were determined with the Dual-Luciferase Reporter Assay
(Promega). The expression of firefly and Renilla luciferase
was within the linear range and no squelching effects were
observed. The activity of the transactivators was calculated
as the ratio of the firefly and Renilla luciferase activities,
and corrected for between-session variation as described
[34].
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